A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer, Colorectal Cancer
Interventions: DRUG: capecitabine RTD|DRUG: capecitabine [Xeloda]|DRUG: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche